Telix Seeks European Approval for Brain Cancer Imaging Agent TLX101-Px
Event summary
- Telix submitted a marketing authorization application (MAA) in Europe for TLX101-Px, its glioma imaging candidate, on February 18, 2026.
- The submission covers major European markets and aims to expand patient access to advanced brain imaging.
- TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx.
- The U.S. New Drug Application (NDA) for TLX101-Px will follow the European submission.
The big picture
Telix's submission for TLX101-Px in Europe marks a strategic move to address the critical unmet need for advanced brain cancer imaging. The company aims to leverage this approval to support its broader therapeutic development program, particularly for glioblastoma. The shift towards commercializing targeted radiopharmaceuticals reflects a broader industry trend towards precision medicine in oncology.
What we're watching
- Regulatory Timing
- Whether the European regulatory process for TLX101-Px will proceed smoothly and on the agreed timeline, given the complexity of radiopharmaceutical approvals.
- Commercial Strategy
- How Telix plans to position TLX101-Px against existing physician-supervised use of 18F-FET in Europe and ensure consistent quality and access.
- Therapeutic Synergy
- The pace at which TLX101-Px can be integrated with TLX101-Tx, Telix's glioblastoma therapy candidate, to enhance treatment decision-making.
Related topics